Development of detecting circulating renal cancer cells that have Death Receptor 5 as a surface marker

本研究的目的是利用肾细胞表面标志物DR-5的荧光标记抗体，检测肾细胞癌患者血液中循环极低体积的癌细胞（外周血循环肿瘤细胞（CTC））。在初步实验中，可以将肾癌细胞计数为CTC。然而，在局限性和转移性肾癌患者的外周血中（分别为15例和4例），DR-5阳性检出率较低，CTC检测困难。此外，对13例患者进行了CTC测量，使用的是首先从肾脏流出的肾静脉中的血液，但由于这是在肾脏切除后进行的，因此存在明显的污染，因此发现它不适合测量CTC。

This research was planned with the objective of detecting cancer cells at extremely low volumes circulating in the blood of renal cell carcinoma patients (circulating tumor cells (CTC) in peripheral blood), using fluorescence-labeled antibodies for DR-5, a surface marker of renal cancer cells.In a preliminary experiment, it was possible to count renal cancer cells as CTC. However, in the peripheral blood of localized and metastatic renal cell carcinoma patients (respectively 15 and 4 patients), the positive detection rate for DR-5 was low, and CTC detection was difficult. Moreover, CTC measurement using the blood in the renal veins that first flowed from the kidneys was performed for 13 patients, but there was significant contamination given that this was subsequent to renal excision, and it was found to be unsuitable for CTC measurement.